VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MM 2021 | Treating later relapses in patients with multiple myeloma

Stefan Knop, MD, University Hospital of Würzburg, Würzburg, Germany, discusses his approach to treating later relapses in patients with multiple myeloma. Prof. Knop highlights the introduction of the anti-CD38 monoclonal antibody daratumumab and outlines the treatment of patients who are refractory to multiple therapies. Prof. Knop also describes the benefits of molecular profiling in refractory patients in order to identify novel actionable targets and the use of JAK2 inhibitors. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter